Skip to search formSkip to main contentSkip to account menu

Somatropin 8.8 MG Cartridge [Saizen]

Known as: SOMATROPIN 8.8 mg in 1.51 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [saizenprep], SOMATROPIN 8.8 mg in 1.51 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Saizen ClickEasy], SAIZEN CLICKEASY KIT 
National Institutes of Health

Related topics

Related topics

19 relations
Brain NeoplasmsCachexiaCartridgeCongestive heart failure

Broader (1)

Pituitary Hormones, Anterior

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Adherence and long-term outcomes of therapy in paediatric patients in Greece using the easypod™ electromechanical device for growth hormone treatment: The phase IV multicentre easypod™ connect…
2018
2018
Patients and Caregivers Perspectives on a Mobile App that Tracks Adherence and Outcomes in Children with Growth Disorders Treated with Recombinant Human Growth Hormone (r-hGH)
Presented at ESPE 2018; September 27-September 29, 2018; Athens, Greece. • easypodTM is an electromechanical autoinjector used… 
2016
2016
A New Reusable Manual Pen Device for Injection of Human Growth Hormone: Results of a Convenience and Functionality Evaluation Study
• The new Saizen® manual pen device consists of a reusable aluminium body and cap, with a multi-use cartridge system, viewing… 
2009
2009
Land Use Planning and Open Space Preservation: Economic Impacts of Low-Density Urbanization and Urban Sprawl
In the United States, dispersion of low density residential areas is typically observed at the urban fringe adjacent to… 
2001
2001
Outcome of growth hormone therapy in children with growth hormone deficiency showing an inadequate response to growth hormone-releasing hormone
Saizen® (recombinant growth hormone [GH]), 0.2 mg/(kg·wk), was given in an open-label fashion for an average of 51 mo to 27… 
1999
1999
Prolonged Growth Response to GH (Saizen®) in Pediatric Subjects with GHD Who Responded Poorly to GHRH (Geref®) Therapy
Prolonged Growth Response to GH (Saizen®) in Pediatric Subjects with GHD Who Responded Poorly to GHRH (Geref®) Therapy 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)